Author

Kristin Grabe-Heyne

Observed names: Grabe-Heyne, Kristin, K Grabe-Heyne, K. Grabe-Heyne

Institution: Medac (Germany)

Observed institution: Medac (Germany)

ORCID: 0000-0001-6991-0473

Observed ORCID: 0000-0001-6991-0473

OpenAlex ID: A5042076602

Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs

2023 · Kristin Grabe-Heyne, Christof Henne, et al. · Frontiers in Oncology · 123

High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma

2024 · Johannes Pöhlmann, Michael Weller, et al. · Frontiers in Oncology · 43

Improved Therapeutic Approaches are Needed to Manage Graft-versus-Host Disease

2021 · Deborah S. Hooker, Kristin Grabe-Heyne, et al. · Clinical Drug Investigation · 12

Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK

2023 · Kristin Grabe-Heyne, Christof Henne, et al. · Journal of Medical Economics · 11

Cost-Utility Analysis of Subcutaneous Methotrexate in the Treatment of Patients with Rheumatoid Arthritis in the UK

2025 · Matthew Tucker, Johannes Pöhlmann, et al. · Advances in Therapy · 1

HSD15 The Economic and Humanistic Burden of Glioma in the United States and Canada

2024 · J Pöhlmann, K Grabe-Heyne, et al. · Value in Health · 1

HSD91 High Costs, Low Quality of Life, Reduced Survival, and Room for Improving Treatment: An Analysis of Burden and Unmet Needs in Glioma

2023 · J. Pöhlmann, M. Weller, et al. · Value in Health · 1

Subcutaneous methotrexate for treating rheumatoid arthritis in Portugal: a cost-utility analysis versus current practice

2026 · Matthew Tucker, Maria João Salvador, et al. · ARP Rheumatology

EE315 Cost Utility of Subcutaneous Methotrexate As a Second-Line Treatment for Moderate to Severe Rheumatoid Arthritis in the UK

2025 · Matthew Tucker, Johannes Pöhlmann, et al. · Value in Health

EPH6 Non-Muscle-Invasive Bladder Cancer: A Review of Burden and Unmet Need

2022 · K Grabe-Heyne, C Henne, et al. · Value in Health

EE563 Evaluating the Cost-Utility of Intravesical Bacillus Calmette-Guérin Versus Radical Cystectomy in Patients With High-Risk Non-Muscle-Invasive Bladder Cancer in the UK

2022 · K Grabe-Heyne, C Henne, et al. · Value in Health

EE363 Improved Therapeutic Approaches Are Needed to Minimise the Burden of Graft-Versus-Host Disease

2022 · D Hooker, K Grabe-Heyne, et al. · Value in Health

Works count: 13

Citation count: 192

H-index: 4

I10-index: 4